Total Payments
$77,637
2024 Payments
$15,248
Companies
26
Transactions
122
Medicare Patients
1,611
Medicare Billing
$292,265
Payment Breakdown by Category
Consulting$57,093 (73.5%)
Other$11,152 (14.4%)
Research$4,600 (5.9%)
Food & Beverage$2,507 (3.2%)
Travel$2,184 (2.8%)
Education$100.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $57,093 | 24 | 73.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,652 | 4 | 12.4% |
| Unspecified | $4,600 | 2 | 5.9% |
| Food and Beverage | $2,507 | 83 | 3.2% |
| Travel and Lodging | $2,184 | 7 | 2.8% |
| Honoraria | $1,500 | 1 | 1.9% |
| Education | $100.00 | 1 | 0.1% |
Payments by Type
General
$73,037
120 transactions
Research
$4,600
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Global Services, LLC | $20,770 | 14 | $0 (2021) |
| GENZYME CORPORATION | $12,250 | 5 | $0 (2022) |
| PFIZER INC. | $8,154 | 10 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $7,756 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,763 | 10 | $0 (2024) |
| Eisai Inc. | $4,888 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $4,813 | 13 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $3,010 | 3 | $0 (2022) |
| Astellas Pharma US Inc | $2,450 | 6 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $2,439 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,248 | 14 | E.R. Squibb & Sons, L.L.C. ($6,694) |
| 2022 | $15,233 | 3 | GENZYME CORPORATION ($12,068) |
| 2021 | $9,113 | 7 | Janssen Global Services, LLC ($5,400) |
| 2020 | $14,139 | 9 | Janssen Global Services, LLC ($9,300) |
| 2019 | $16,564 | 21 | Janssen Global Services, LLC ($6,070) |
| 2018 | $2,701 | 44 | PFIZER INC. ($1,950) |
| 2017 | $4,639 | 24 | Bayer HealthCare Pharmaceuticals Inc. ($4,240) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $3,420.00 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $34.01 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $7.41 | General |
| Category: Oncology | ||||||
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,541.00 | General |
| 07/24/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,370.00 | General |
| Category: Oncology | ||||||
| 07/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $116.92 | General |
| 07/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,811.00 | General |
| 07/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $100.50 | General |
| 06/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 06/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $85.41 | General |
| Category: Oncology | ||||||
| 01/25/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 11/09/2022 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 11/08/2022 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $12,068.00 | General |
| 06/10/2022 | Astellas Pharma US Inc | Xtandi (Drug) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 12/15/2021 | Blue Earth Diagnostics Limited | Axumin (Drug) | Consulting Fee | Cash or cash equivalent | $1,062.50 | General |
| Category: Diagnostic Imaging | ||||||
| 12/03/2021 | Janssen Global Services, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: Oncology | ||||||
| 10/19/2021 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 10/08/2021 | Janssen Global Services, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: Oncology | ||||||
| 06/25/2021 | Janssen Global Services, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: Oncology | ||||||
| 03/19/2021 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: Oncology | ||||||
| 02/26/2021 | Janssen Global Services, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: Oncology | ||||||
| 12/18/2020 | Janssen Global Services, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AXITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 421 | 718 | $401,059 | $58,409 |
| 2022 | 8 | 362 | 642 | $324,365 | $51,731 |
| 2021 | 10 | 444 | 1,062 | $615,588 | $108,945 |
| 2020 | 10 | 384 | 786 | $314,200 | $73,180 |
Total Patients
1,611
Total Services
3,208
Medicare Billing
$292,265
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 259 | $130,795 | $20,883 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 119 | 214 | $85,678 | $11,310 | 13.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 79 | $42,265 | $5,807 | 13.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 43 | $33,750 | $5,441 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $23,160 | $3,564 | 15.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $21,560 | $3,247 | 15.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $20,745 | $2,898 | 14.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 15 | 15 | $9,345 | $1,606 | 17.2% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 12 | 12 | $13,343 | $1,365 | 10.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $12,648 | $1,219 | 9.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 15 | $7,770 | $1,069 | 13.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 268 | $135,340 | $22,948 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 114 | 183 | $73,200 | $9,560 | 13.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 74 | $42,550 | $7,032 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 41 | $27,880 | $5,337 | 19.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $20,265 | $3,680 | 18.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $10,010 | $1,543 | 15.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 14 | $6,580 | $1,188 | 18.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 25 | 28 | $8,540 | $442.71 | 5.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 50 | 301 | $237,790 | $48,160 | 20.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 105 | 260 | $128,972 | $22,919 | 17.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 136 | 248 | $99,278 | $13,912 | 14.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 69 | $37,035 | $6,690 | 18.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 43 | $27,960 | $5,886 | 21.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 24 | 24 | $22,280 | $4,113 | 18.5% |
About Dr. Benjamin Gartrell, MD
Dr. Benjamin Gartrell, MD is a Internal Medicine healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043414451.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Gartrell, MD has received a total of $77,637 in payments from pharmaceutical and medical device companies, with $15,248 received in 2024. These payments were reported across 122 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($57,093).
As a Medicare-enrolled provider, Gartrell has provided services to 1,611 Medicare beneficiaries, totaling 3,208 services with total Medicare billing of $292,265. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Bronx, NY
- Active Since 06/12/2007
- Last Updated 10/27/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1043414451
Products in Payments
- ERLEADA (Drug) $15,697
- Erleada (Drug) $12,421
- INLYTA (Drug) $7,969
- Lenvima (Drug) $4,861
- Xofigo (Drug) $4,280
- Nubeqa (Drug) $3,476
- Xtandi (Drug) $2,411
- FOTIVDA (Drug) $1,500
- PADCEV (Biological) $1,150
- Axumin (Drug) $1,063
- ZYTIGA (Drug) $412.34
- TECENTRIQ (Biological) $155.59
- NO PRODUCT DISCUSSED (Drug) $138.23
- Neulasta (Biological) $80.39
- XGEVA (Biological) $73.70
- OPDIVO (Biological) $68.15
- Cabozantinib (Drug) $66.73
- XTANDI (Drug) $66.53
- AFINITOR (Drug) $63.62
- IMBRUVICA (Drug) $61.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bronx
Timothy Kanter, M.d, M.D
Internal Medicine — Payments: $865,160
Internal Medicine $865,160
Dr. Jason Leider, M.d, M.D
Internal Medicine — Payments: $759,257
Internal Medicine $759,257
Bulent Atac, Md, MD
Internal Medicine — Payments: $654,500
Internal Medicine $654,500
Shervin Mortazavi, M.d, M.D
Internal Medicine — Payments: $402,598
Internal Medicine $402,598
Dr. Elizabeth Jenny-Avital
Internal Medicine — Payments: $176,355
Internal Medicine $176,355
Vivek Gumaste, M.d, M.D
Internal Medicine — Payments: $163,229
Internal Medicine $163,229